TY - JOUR
T1 - Rifampin Prophylaxis for Contacts of Haemophilus influenzae Type b Disease
AU - Cox, Frederick
AU - Trincher, Rose
AU - Rissing, J. Peter
AU - Patton, Maurice
AU - Mccracken, George H.
AU - Granoff, Dan M.
PY - 1981/3/13
Y1 - 1981/3/13
N2 - Rifampin prophylaxis (20 mg/kg once daily for four days) was used in close contacts of children with Haemophilus influenzae type b (HIB) disease. Two hours after a dose, the concentration of rifampin in serum and saliva exceeded the minimum bactericidal concentrations of organisms obtained from four of the carriers. In both a randomized prospective and an open study, nasopharyngeal carriage was eradicated in 37 (95%) of 39 contacts. No cases of serious H influenzae disease occurred in four to six months of follow-up. At the dose and treatment schedule used, rifampin was safe and effective for eradication of HIB carriage. (JAMA 1981;245:1043-1045).
AB - Rifampin prophylaxis (20 mg/kg once daily for four days) was used in close contacts of children with Haemophilus influenzae type b (HIB) disease. Two hours after a dose, the concentration of rifampin in serum and saliva exceeded the minimum bactericidal concentrations of organisms obtained from four of the carriers. In both a randomized prospective and an open study, nasopharyngeal carriage was eradicated in 37 (95%) of 39 contacts. No cases of serious H influenzae disease occurred in four to six months of follow-up. At the dose and treatment schedule used, rifampin was safe and effective for eradication of HIB carriage. (JAMA 1981;245:1043-1045).
UR - http://www.scopus.com/inward/record.url?scp=84944965146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944965146&partnerID=8YFLogxK
U2 - 10.1001/jama.1981.03310350031018
DO - 10.1001/jama.1981.03310350031018
M3 - Article
C2 - 6970272
AN - SCOPUS:84944965146
SN - 0098-7484
VL - 245
SP - 1043
EP - 1045
JO - JAMA: The Journal of the American Medical Association
JF - JAMA: The Journal of the American Medical Association
IS - 10
ER -